Equities researchers at Lake Street Capital began coverage on shares of Assertio (NASDAQ:ASRT – Get Rating) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a "buy" rating and a $7.00 price target on the stock. Lake Street Capital's target price points to a potential upside of 167.18% from the company's previous close.

A number of other brokerages have also commented on ASRT. TheStreet raised shares of Assertio from a "d" rating to a "c-" rating in a research report on Wednesday, August 3rd. StockNews.com lowered Assertio from a "buy" rating to a "hold" rating in a research report on Monday, October 31st. Finally, Roth Capital restated a "buy" rating on shares of Assertio in a research note on Wednesday, August 24th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.00.

Assertio Price Performance

ASRT opened at $2.62 on Monday. The business has a fifty day moving average of $2.39 and a 200 day moving average of $2.79. The stock has a market cap of $126.23 million, a P/E ratio of 4.85, a PEG ratio of 0.53 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.00 and a debt-to-equity ratio of 0.39. Assertio has a 52-week low of $1.19 and a 52-week high of $4.44.

Institutional Trading of Assertio

Several hedge funds and other institutional investors have recently bought and sold shares of ASRT. Russell Investments Group Ltd. bought a new stake in Assertio during the second quarter valued at about $28,000. Sigma Planning Corp bought a new stake in shares of Assertio in the 2nd quarter valued at about $32,000. Virtu Financial LLC purchased a new position in shares of Assertio in the 3rd quarter worth approximately $37,000. Advisor Group Holdings Inc. lifted its position in Assertio by 2,983.7% during the first quarter. Advisor Group Holdings Inc. now owns 13,229 shares of the company's stock valued at $38,000 after acquiring an additional 12,800 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in Assertio during the second quarter valued at approximately $40,000. Institutional investors own 27.93% of the company's stock.

Assertio Company Profile

(Get Rating)

Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

Recommended Stories

• Get a free copy of the StockNews.com research report on Assertio (ASRT)
• The Cheesecake Factory Shows You Can Have It and Eat It Too
• Two EV Stocks That Could Rally Into Year-End
• 3 High Yields The Institutions Are Buying
• Can Activision Blizzard Rally Into Year End?
• Despite Financials, Twiliio is One To Watch

Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.